Boosting IoT data valorization through the adoption of DLT

During the last decade Internet of Things has become one of the key technologies in supporting digital transformation of several ecosystems such urban or industry ones. The huge amount of data generated in such contexts as well as the imperative requirements in terms of trustworthiness, authenticity and integrity make compulsory the adoption of the proper solutions fitting those requirements. This paper presents the design, implementation and validation of a distributed ledger technology architecture emphasizing services linked to data valorization.This work is supported by the TOKEN Project: “Transformative Impact Of BlocKchain tEchnologies iN Public Services”, Grant Agreement 870603, belonging to the H2020 Framework Program. The authors want to acknowledge the valuable work carried out by the colleagues participating in this initiative

Historia Antigua y Transferencia de conocimiento a través del Aprendizaje Servicio

Este proyecto presenta una colaboración entre el Área de Historia Antigua del Departamento de Prehistoria, Historia Antigua y Arqueología de la UCM, el Departamento de Griego del IES Miguel Catalán de Coslada y el Museo Arqueológico Nacional (MAN). Combinando los principios pedagógicos del Aprendizaje Servicio y del Aprendizaje Cooperativo hemos construido una red de trabajo entre los alumnos de tercero del Grado de Historia de la UCM y Primero de Bachillerato del IES Miguel Catalán con tres objetivos principales interrelacionados: primero, introducir en la historia y la cultura del mundo clásico a población mayor, con o sin grados de dependencia, de los municipios de Coslada y San Fernando, a través de la interacción con las nuevas generaciones; segundo, impulsar principios colaborativos entre alumnos de Bachillerato y alumnos universitarios con un fin social, contribuyendo de este modo a hacer más práctica la formación curricular, tanto la del instituto como la universitaria, y a enfatizar la capacidad que esta tiene de transferir conocimiento, capacidades y competencias a la sociedad que sustenta su existencia. Tercero, acercar las posibilidades de la formación universitaria a estudiantes que a menudo no la tienen entre sus planes de futuro. Contamos para ello con el apoyo del Museo Arqueológico Nacional, que es donde los alumnos han llevado a cabo las visitas organizadas y los talleres históricos para los mayores

Sloan Digital Sky Survey IV: Mapping the Milky Way, Nearby Galaxies, and the Distant Universe

We describe the Sloan Digital Sky Survey IV (SDSS-IV), a project encompassing three major spectroscopic programs. The Apache Point Observatory Galactic Evolution Experiment 2 (APOGEE-2) is observing hundreds of thousands of Milky Way stars at high resolution and high signal-to-noise ratios in the near-infrared. The Mapping Nearby Galaxies at Apache Point Observatory (MaNGA) survey is obtaining spatially resolved spectroscopy for thousands of nearby galaxies (median $z\sim 0.03$). The extended Baryon Oscillation Spectroscopic Survey (eBOSS) is mapping the galaxy, quasar, and neutral gas distributions between $z\sim 0.6$ and 3.5 to constrain cosmology using baryon acoustic oscillations, redshift space distortions, and the shape of the power spectrum. Within eBOSS, we are conducting two major subprograms: the SPectroscopic IDentification of eROSITA Sources (SPIDERS), investigating X-ray AGNs and galaxies in X-ray clusters, and the Time Domain Spectroscopic Survey (TDSS), obtaining spectra of variable sources. All programs use the 2.5 m Sloan Foundation Telescope at the Apache Point Observatory; observations there began in Summer 2014. APOGEE-2 also operates a second near-infrared spectrograph at the 2.5 m du Pont Telescope at Las Campanas Observatory, with observations beginning in early 2017. Observations at both facilities are scheduled to continue through 2020. In keeping with previous SDSS policy, SDSS-IV provides regularly scheduled public data releases; the first one, Data Release 13, was made available in 2016 July

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years